# Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

> **NCT03474094** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Leon Berard** · enrollment: 62 (actual)

## Conditions studied

- Sarcoma,Soft Tissue

## Interventions

- **COMBINATION_PRODUCT:** Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
- **COMBINATION_PRODUCT:** 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
- **COMBINATION_PRODUCT:** Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.

## Key facts

- **NCT ID:** NCT03474094
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474094, "Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03474094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*